Under which situations might the International Trade Commission (ITC) be the right choice for biosimilar patent disputes instead of federal district court? A panel discussed these questions at the ACI 10th Summit on Biosimilars on Monday in New York City.
Under which situations might the International Trade Commission (ITC) be the right choice for biosimilar patent disputes instead of federal district court?
A panel discussed these questions at the ACI 10th Summit on Biosimilars on Monday in New York City, although the panelists noted that as of yet, the administrative body, which oversees US trade laws, has yet to hear a case involving a biologic or biosimilar. In that respect, the conversation was largely theoretical, although all 3 panelists expect that to change in coming years.
The ITC has 2 remedies available to enforce Section 337 of the Tariff Act: an exclusion order to prevent the importation of articles into the United States, and a cease-and-desist order directed to US companies to prevent sales of items that are already in the country.
Most of the cases before the ITC, which are resolved more swiftly before the ITC than they would be in district court, generally relate to consumer goods.
The so-called 337 investigations are carried out by the United States, said moderator Jonathan Bachand, JD, a partner at Knobbe Martens, and involve trade secrets, trademark infringements, patent infringements, or “unfair methods of competition and unfair acts.”
Bachand said he could imagine a potential case in which an employee of a maker of a reference product leaves and goes to work for a biosimilar company, and the former employer believes that trade secrets where misappropriated.
Kevin S. Prussia, JD, a partner at Wilmer Cutler Pickering Hale and Dorr LLP, said questions could also be raised in situations involving “skinny” labeling, wherein a biosimilar product seeks a narrower indication that what is approved on the original reference product.
Another way an ITC proceeding could be used is as a complement to a district court proceeding, Prussia said, given the timing of the patents involved.
“There’s this sweet spot between getting a decision on your patents quickly to incentivize a biosimilar to launch,” he said. But he said he doesn’t see the ITC being a substitute for district court litigation.
A type of case that cannot be brought before the ITC, however, is demonstrated in the Amarin case, Bachand said, where a party cannot attempt to use it as a “private enforcement action.” Earlier this year, the ITC refused to back Amarin Pharma’s claim alleging that the import and sale of certain omega 3 fish oil products constituted unfair competition because they were unlawfully labelled and marked as “dietary supplements” but were in fact “new drugs.”
Amarin makes Vascepa, a high-dose fish oil pill that it is seeking approval of supplemental New Drug Application after trial results showed that it cut cardiovascular events.
The ITC determined the Section 337 claims were precluded by the Food, Drug and Cosmetic Act (FDCA) and required a determination of whether the products at issue violated the FDCA.
Importation of products is one of the necessary requirements in order to have standing before the ITC. Companies may also try to prove “imminent importation” (for example, showing that a company is having discussions or trying to seed a new market with their product).
Bachand asked the panel to consider what is a good timeframe for going to the FTC.
Paul Atkinson, JD, a director at Sterne Kessler, said the release of the180-day notice might be 1 such point in time at which to consider a filing; earlier than that might raise questions, he said.
One of the factors the ITC considers is public interest. There are 4 ways the ITC can consider the public interest as a limit in exclusion orders, Prussia said; this is the area where it is possible that biosimilars could potentially demonstrate a public interest factor:
However, parties should be judicious in deciding which claims to assert before the ITC, Bachand said.
In addition, the filing and/or start of an inter partes review will not delay an ITC investigation, he noted.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.